 |
27 Products |  |
14 Diseases | | 27 Products |
|
13 Trials |  |
837 News |  |
| «123456789» |
- | VGX-1027 / GeneOne
Journal: The potent immunomodulatory compound VGX-1027 regulates inflammatory mediators in CD4 T cells, which are concomitant with the prevention of neuroimmune dysregulation in BTBR T Itpr3/J mice. (Pubmed Central) - Nov 27, 2019
Moreover, this agent was also found to significantly decrease IL-1β, IL-6, TNF-α, IFN-γ, COX-2, and NOS2 levels and increase IL-10 expression at the protein and mRNA level in brain tissues. Based on results using BTBR mice, our data provide the first evidence that VGX-1027 could potentially be used for the amelioration of autism-like symptoms.
- ||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Metastases: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Nov 15, 2019
P1b/2a, N=35, Active, not recruiting, Sponsor: MedImmune LLC
Based on results using BTBR mice, our data provide the first evidence that VGX-1027 could potentially be used for the amelioration of autism-like symptoms. N=50 --> 35
- || INO-4500 / Inovio
Enrollment closed: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2019
P1, N=60, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=50 --> 35 Recruiting --> Active, not recruiting
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) (Prince George's Exhibition Halls AB) - Nov 2, 2019 - Abstract #SITC2019SITC_1307;
INO-5401 + INO-9012 with cemiplimab has an acceptable safety profile, is immunogenic and is potentially efficacious in patients with newly-diagnosed GBM. This combination is promising; survival results will be updated next year.
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment change, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Oct 1, 2019
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
This combination is promising; survival results will be updated next year. N=85 --> 35
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment closed: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (clinicaltrials.gov) - Oct 1, 2019
P2, N=23, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=85 --> 35 Recruiting --> Active, not recruiting
- | neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
Enrollment change: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) - Sep 24, 2019
P1, N=6, Not yet recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting N=30 --> 6
- | INO-4500 / Inovio
New P1 trial, Combination therapy: Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) - Sep 16, 2019
P1, N=225, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment closed, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Aug 14, 2019
P1/2, N=85, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=30 --> 6 Recruiting --> Active, not recruiting
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Metastases: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Aug 1, 2019
P1b/2a, N=50, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker: Clinical and Immunological Biomarkers for Histologic Regression of High Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. (Pubmed Central) - Jul 26, 2019
Quantitative measures associated with an effector immune response to VGX-3100 antigens were associated with lesion regression. Consequently, these analyses indicate that certain immunologic responses associate with successful resolution of HPV-induced pre-malignancy, with particular emphasis on the upregulation of perforin in the immunotherapy induced immune response.
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment closed: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Jul 24, 2019
P3, N=200, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Consequently, these analyses indicate that certain immunologic responses associate with successful resolution of HPV-induced pre-malignancy, with particular emphasis on the upregulation of perforin in the immunotherapy induced immune response. Recruiting --> Active, not recruiting
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment closed, Combination therapy: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) (clinicaltrials.gov) - Jul 24, 2019
P2, N=36, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Biomarker, Enrollment change, IO biomarker, Metastases: PORTER: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (clinicaltrials.gov) - Jul 17, 2019
P1, N=45, Recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
Recruiting --> Active, not recruiting N=30 --> 45
- | Biomarker, Enrollment open, IO biomarker, Metastases: PORTER: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (clinicaltrials.gov) - Jul 11, 2019
P1, N=30, Recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
N=30 --> 45 Not yet recruiting --> Recruiting
- | neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
New P1 trial, Checkpoint inhibition: Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) - Jul 10, 2019
P1, N=30, Not yet recruiting, Sponsor: Washington University School of Medicine
- |||| MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial, PD(L)-1 Biomarker: Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients (clinicaltrials.gov) - Jun 27, 2019
P2, N=66, Not yet recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- || Biomarker, Trial initiation date, IO biomarker, Metastases: PORTER: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (clinicaltrials.gov) - Jun 13, 2019
P1, N=30, Not yet recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
Not yet recruiting --> Recruiting Initiation date: Mar 2019 --> Jun 2019
- | INO-1400 / Inovio, Syncon vaccines (H1+H5) / Inovio
Journal, IO Biomarker: Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein-Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth. (Pubmed Central) - May 30, 2019
LMP2Avax was able to drive immunity that impacted EBV-antigen-positive tumor growth. These studies suggest that engineered EBV latent protein vaccines deserve additional study as potential agents for immunotherapy of EBV-driven cancers.
- ||| INO-4500 / Inovio
Enrollment open: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - May 12, 2019
P1, N=60, Recruiting, Sponsor: Inovio Pharmaceuticals
These studies suggest that engineered EBV latent protein vaccines deserve additional study as potential agents for immunotherapy of EBV-driven cancers. Not yet recruiting --> Recruiting
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Trial primary completion date: VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 (clinicaltrials.gov) - Apr 16, 2019
P2, N=24, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Mar 2021
- |||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment open: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Apr 11, 2019
P3, N=198, Recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2020 --> Mar 2021 Not yet recruiting --> Recruiting
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment closed, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Mar 29, 2019
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || INO-4700 / GeneOne, Inovio
Enrollment closed: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Mar 27, 2019
P1/2, N=60, Active, not recruiting, Sponsor: GeneOne Life Science, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Trial primary completion date: REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Mar 8, 2019
P3, N=198, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Trial completion date: Aug 2020 --> Apr 2021 | Trial primary completion date: Aug 2019 --> Apr 2020
- ||| bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Trial primary completion date: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Mar 7, 2019
P3, N=198, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Aug 2020 --> Apr 2021 | Trial primary completion date: Aug 2019 --> Apr 2020 Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Dec 2020 --> Apr 2021
- || INO-A002 / Inovio
Enrollment open: A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - Feb 10, 2019
P1, N=24, Recruiting, Sponsor: University of Pennsylvania
Trial completion date: Dec 2020 --> May 2021 | Trial primary completion date: Dec 2020 --> Apr 2021 Not yet recruiting --> Recruiting
- || Biomarker, New P1 trial, IO biomarker, Metastases: PORTER: Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (clinicaltrials.gov) - Feb 8, 2019
P1, N=30, Not yet recruiting, Sponsor: Parker Institute for Cancer Immunotherapy
- || INO-A002 / Inovio
New P1 trial: A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) - Feb 5, 2019
P1, N=24, Not yet recruiting, Sponsor: University of Pennsylvania
- ||| INO-4500 / Inovio
New P1 trial: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers (clinicaltrials.gov) - Jan 16, 2019
P1, N=60, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial completion date, Trial primary completion date: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Nov 24, 2018
P3, N=198, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Mar 2021 --> Dec 2020 | Trial primary completion date: Mar 2021 --> Dec 2020
- | Trial completion, Combination therapy, Surgery: hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (clinicaltrials.gov) - Nov 19, 2018
P1, N=93, Completed, Sponsor: Inovio Pharmaceuticals
Trial completion date: Mar 2021 --> Dec 2020 | Trial primary completion date: Mar 2021 --> Dec 2020 Active, not recruiting --> Completed
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Nov 15, 2018
P2, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
New P3 trial: REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL) (clinicaltrials.gov) - Oct 26, 2018
P3, N=198, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- | INO-4700 / GeneOne, Inovio
New P1/2 trial: Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Oct 25, 2018
P1/2, N=60, Recruiting, Sponsor: GeneOne Life Science, Inc.
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-3106 / Inovio
Trial completion: Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies (clinicaltrials.gov) - Oct 16, 2018
P1, N=3, Completed, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Oct 5, 2018
P2, N=77, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Trial completion date: Jan 2021 --> Jan 2020
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Enrollment open, Trial primary completion date: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) - Sep 24, 2018
P2, N=80, Recruiting, Sponsor: AIDS Malignancy Consortium
Trial completion date: Jan 2021 --> Jan 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2020 --> Jan 2021
- | Trial completion, Enrollment change: WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation (clinicaltrials.gov) - Sep 7, 2018
P2, N=23, Completed, Sponsor: University Hospital Southampton NHS Foundation Trust
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2020 --> Jan 2021 Suspended --> Completed | N=184 --> 23
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-4201 / Inovio
Trial completion: Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers (clinicaltrials.gov) - Aug 2, 2018
P1, N=240, Completed, Sponsor: Inovio Pharmaceuticals
Suspended --> Completed | N=184 --> 23 Active, not recruiting --> Completed
- | INO-4700 / GeneOne, Inovio
Trial completion: Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers (clinicaltrials.gov) - Aug 2, 2018
P1, N=75, Completed, Sponsor: GeneOne Life Science, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | INO-6145 / Inovio, PENNVAX-GP (HIV DNA vaccine) / Inovio, rocakinogene sifuplasmid (INO-9012) / Inovio
New P1/2 trial: Therapeutic Vaccination in Treated HIV Disease (clinicaltrials.gov) - Jul 29, 2018
P1/2, N=60, Recruiting, Sponsor: Steven Deeks
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
New P2 trial: VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) - Jul 26, 2018
P2, N=80, Not yet recruiting, Sponsor: AIDS Malignancy Consortium
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-3106 / Inovio
Enrollment closed, Trial completion date, Trial primary completion date: Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies (clinicaltrials.gov) - Jul 26, 2018
P1, N=3, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
- | INO-1800 / Inovio, INO-9112 / Inovio
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects (clinicaltrials.gov) - Jul 23, 2018
P1, N=90, Completed, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018 | Trial primary completion date: Aug 2018 --> May 2018
- || MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial initiation date, Metastases: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers (clinicaltrials.gov) - Jul 16, 2018
P2, N=77, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial completion date: Aug 2018 --> May 2018 | Trial primary completion date: Aug 2018 --> May 2018 Initiation date: Jun 2018 --> Sep 2018
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Jun 25, 2018
P1/2, N=85, Recruiting, Sponsor: Inovio Pharmaceuticals
Initiation date: Jun 2018 --> Sep 2018 Not yet recruiting --> Recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jun 18, 2018
P1/2, N=52, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | bizalimogene ralaplasmid (VGX-3100) / Inovio
Trial primary completion date, Combination therapy: Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) (clinicaltrials.gov) - Jun 15, 2018
P2, N=36, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2019 --> Aug 2020
- | MEDI0457 / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck Cancer (clinicaltrials.gov) - Jun 12, 2018
P1b/2a, N=40, Recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Mar 2020 --> Aug 2020 | Trial primary completion date: Mar 2020 --> Aug 2020